Presentation Information
[P03-398]Translational Biotechnology for Population Health: Leveraging RICCA Isothermal Amplification and BioMuRun Robotics for Pandemic Readiness
Manish Biyani1, ○Anjali Pandit1, Yuri Ishii1, Shinsuke Fujiwara1 (1. Kwansei Gakuin University (Japan))
Keywords:
Isothermal nucleic acid amplification,Portable gel electrophoresis,Recombinase polymerase amplification,Tuberculosis
Rapid, affordable, and scalable diagnostics are essential to building resilient health systems in the pandemic era. This work demonstrates how translational biotechnology can reshape population health by integrating two next-generation platforms.
First, the RICCA (RNA Isothermal Co-assisted and Coupled Amplification) assay, a robust approach comparable to RT-PCR, simplifies molecular workflows while delivering sensitive, reliable detection in resource-limited settings. Through the optimization and freeze-drying of an engineered enzyme cocktail, this 15-minute assay operates at a constant 41°C. These room-temperature-storable kits are highly effective for the on-site molecular diagnosis of COVID-19 and other infectious diseases, such as Tuberculosis.
Second, BioMuRun, representing the rebirth of gel electrophoresis, provides a portable, fast, and user-friendly separation technology optimized for point-of-care applications. Together, these systems modernize two foundational pillars of biotechnology, reducing costs while expanding access and surveillance capabilities. Case studies on the detection of the SARS-CoV-2 gene and the 85b gene for TB will highlight performance metrics, deployment lessons, and opportunities for localized manufacturing. The presentation outlines a strategic roadmap to integrate RICCA and BioMuRun into robotic ecosystems to enhance preparedness for Society 5.0.
First, the RICCA (RNA Isothermal Co-assisted and Coupled Amplification) assay, a robust approach comparable to RT-PCR, simplifies molecular workflows while delivering sensitive, reliable detection in resource-limited settings. Through the optimization and freeze-drying of an engineered enzyme cocktail, this 15-minute assay operates at a constant 41°C. These room-temperature-storable kits are highly effective for the on-site molecular diagnosis of COVID-19 and other infectious diseases, such as Tuberculosis.
Second, BioMuRun, representing the rebirth of gel electrophoresis, provides a portable, fast, and user-friendly separation technology optimized for point-of-care applications. Together, these systems modernize two foundational pillars of biotechnology, reducing costs while expanding access and surveillance capabilities. Case studies on the detection of the SARS-CoV-2 gene and the 85b gene for TB will highlight performance metrics, deployment lessons, and opportunities for localized manufacturing. The presentation outlines a strategic roadmap to integrate RICCA and BioMuRun into robotic ecosystems to enhance preparedness for Society 5.0.
Comment
To browse or post comments, you must log in.Log in